A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.